an anti-inflammatory adipokine that is expressed as an abundant, multimeric protein. Circulating adiponectin levels display a strong inverse correlation with body mass index (3) . Adiponectin has a well-described role in maintaining metabolic homeostasis (2) . Adiponectin also functions to protect the heart and vasculature from stress in a variety of models (3) (4) (5) (6) (7) . Our labs and others have previously shown that adiponectin promotes vascular function and angiogenesis using endothelial cell culture systems (8, 9) , mouse models of tumor growth (10, 11 ) and a mouse model of ischemic hind limb revascularization (12, 13) .
While it is clear that adiponectin has vascular-protective actions, the receptor(s) that mediate these effects are unknown. Recent studies have identified AdipoR1 and AdipoR2 as the receptors responsible for mediating the metabolic effects of adiponectin in both skeletal muscle and liver, although the reported metabolic phenotypes of AdipoR1-and AdipoR2-deficient strains are somewhat contradictory (14) (15) (16) (17) (18) (19) (20) . AdipoR1 and AdipoR2 are widely expressed seven transmembrane receptors with the opposite topology as G-protein coupled receptors. AdipoR1 preferentially binds globular adiponectin while AdipoR2 has equal affinities for globular and fulllength adiponectin (14) . A third candidate receptor is T-cadherin, a GPI-anchored protein which binds the hexameric and high molecular weight isoforms of adiponectin (21) .
T-cadherin was first identified over two decades ago as an axon guidance molecule (22) and modulator of neural crest cell migration (23) . It is now appreciated that T-cadherin has functions that extend beyond the typical cadherin behavior of cell-to-cell adhesion. T-cadherin is highly expressed in the vasculature including endothelial cells (24) , smooth muscle cells (25) and pericytes (26) . It has been implicated in modulation of angiogenic activities in cultured endothelial cells; however, some studies report that it promotes angiogenesis (27) (28) (29) (30) (31) , whereas others report its attenuation (32, 33) . Importantly, T-cadherin has been shown to localize adiponectin to tumor vasculature and heart tissue (31) . In human subjects, single nucleotide polymorphisms in CDH13, the gene encoding T-cadherin, are associated with circulating levels of adiponectin (34) (35) (36) (37) (38) (39) . Genome wide association studies have also identified links between CDH13 and cancer (40) , blood pressure (41) , blood lipid levels (42) , metabolic syndrome (43, 44) , type II diabetes and ischemic stroke (44) . Given its high level of expression on vascular cells and its role in modulating angiogenic behavior, we hypothesized that the T-cadherin-adiponectin interaction would be important for the revascularization activity of this adipokine in ischemic tissue.
The aim of this study was to determine if expression of T-cadherin is required for the revascularization activity of adiponectin in the ischemic hind limbs of mice, a model of peripheral artery disease (45) . The first objective was to determine if T-cadherin-deficiency in mice phenocopies the impairment in revascularization that is observed in adiponectin-deficient mice. Next, we assessed whether T-cadherin is essential for the pro-vascularization effects of adiponectin by comparing the responses of adiponectindeficient mice and T-cadherin-deficient mice to the administration of exogenous adiponectin. Finally, we examined whether cultured, Tcadherin-deficient endothelial cells are defective in their pro-angiogenic responses to exogenously administered adiponectin in vitro.
T-Cadherin promotes revascularization
and nerve of one limb were permanently ligated. Downstream collateral branches were severed and a small section of the ligated femoral artery, vein and nerve was excised. The wound was closed using surgical staples which remained in place for 10-14 days after surgery. Limb perfusion was monitored before surgery, after surgery and at the following time points: day 3, day 7, day 14, day 21 and day 28 by laser Doppler perfusion imaging (LDPI). Data were analyzed as a blood flow ratio (ischemic/nonischemic) to control for body temperature and environmental conditions.
Hydrodynamic plasmid delivery − In some experiments, pLEV113-mADIPO-hFc (LakePharma, Belmont, CA), an adiponectin-Fc fusion construct (adiponectin plasmid), or pLEV113-MCS (control plasmid), were injected into mice 7 days prior to hind limb ischemia surgery. Adiponectin or control plasmid (24µg) was injected via the tail vein into restrained mice in 2.0-2.5mL total saline volume (10% of body weight) in 5 seconds according to the protocol in (46) .
ELISA − Blood was harvested from mice either by tail vein bleed or cardiac puncture. After clotting at room temperature, samples were centrifuged at 7,000rpm and serum was isolated. Serum adiponectin concentration was determined by ELISA (B-Bridge, Cupertino, CA) per the manufacturers' instructions.
Treadmill − To assess limb function, at baseline and 10 days post-hind limb ischemia surgery, maximum treadmill running distance was determined. In order to acclimate to the equipment, mice were trained for 10 minutes prior to the start of the experiment. The trial began at a speed of 5 meters/minute. The belt speed was increased by 2 meters/minute every 5 minutes. The trial was stopped when mice were exposed to the stimulus at the rear of the treadmill for 30 seconds.
Western blotting − Gastrocnemius muscle and epididymal adipose tissue were harvested from 10 week-old male mice and snap frozen. Tissue was homogenized using RIPA buffer containing protease inhibitors and 100mM PMSF. Samples were centrifuged at 14,000rpm for 10 minutes. Protein concentration of supernatant was assessed by Pierce's (Thermo Fisher Pierce Protein Biology Products, Rockford, IL) bicinchoninic acid (BCA) assay. Serum or tissue lysate were resolved by SDS-PAGE and transferred to a PVDF membrane. Native western blots of the adiponectin isoforms were performed using non-reduced, non-denatured protein samples. Membranes were blocked with 5% nonfat milk in PBS + 0.1% Tween for 1 hour at room temperature. Primary antibody (1:1,000) was added to the membrane overnight at 4°C in blocking buffer. Adiponectin (R&D Systems, Minneapolis, MN), T-cadherin (R&D Systems), tubulin (Santa Cruz Biotechnology, Inc., Dallas, TX), and β-actin (Cell Signaling Technology, Inc., Danvers, MA) antibodies were used. The membrane was then incubated with secondary HRP-conjugated antibodies (1:5,000) for 1 hour at room temperature and developed using SuperSignal West Pico Chemiluminescent Substrate (Pierce) and Amersham Hyperfilm (GE Healthcare Biosciences, Pittsburgh, PA).
Immunofluorescence of skeletal muscle tissue and large vessels − Gastrocnemius muscles from WT, APN-KO, Tcad-KO, AdipoR1 KO and AdipoR2 KO mice were embedded in OCT compound. Cryostat sections of 5µm were cut. Specimens were fixed by 4% paraformaldehyde for 15 minutes. Non-specific binding sites were blocked with 3% horse serum and 3% bovine serum albumin in PBS for 1 hour at room temperature. Then, samples were incubated with both goat polyclonal anti-T-cadherin antibody (R&D Systems) and rabbit polyclonal antiadiponectin antibody (ThermoScientific, Billerica, MA) overnight at 4ºC, followed by incubation with anti-goat IgG conjugated with Alexa Fluor 488 (Life Technologies, Grand Island, NY) for detection of T-cadherin and anti-rabbit IgG conjugated with Alexa Fluor 594 (Life Technologies) for detection of adiponectin. DAPI was used as a nuclear stain. Images were recorded using Zeiss LSM 710-Live Duo scan confocal microscopy.
Immunofluorescence of muscle capillaries -Rectus femoris muscle from WT mice was frozen in OCT compound, and 24 µm cryostat sections were cut, collected on slides and fixed with acetic acid:ethanol (30%:70%) for 5 minutes at room temperature. Samples were incubated simultaneously with rabbit polyclonal antiadiponectin antibody (Affinity BioReagents, Golden, CO), goat polyclonal anti-T-cadherin antibody (R&D Systems), and rat monoclonal anti-CD31 antibody (BD Biosciences, San Jose, Immunoprecipitation -Confluent HUVECs were cultured with serum-free EBM-2 medium (Lonza, Hopkinton, MA) for 16 hours and then treated with 25µg/ml HMW rAPN (BioVendor) for 60 minutes. Cells were washed with PBS and cross-linked with 2.5mmol/l dimethyl 3,3'-dithiopionimidate dihydrochloride (Sigma-Aldrich) for 60 minutes at room temperature. They were washed with PBS and treated with lysis buffer containing protease & phosphatase inhibitor cocktails (Thermo Scientific). Cell lysates were incubated with normal rabbit IgG (Cell Signaling) or antiadiponectin (Abcam, Cambridge, MA) antibodies at 4°C overnight and then Magnetic Protein G beads (Dynabeads Co-Immunoprecipitation Kit, Life technologies) were added. After a 1 hour incubation (room temperature) the beads were washed and target antigen was eluted with elution buffer and SDS sample buffer (Bio-Rad Laboratories, Hercules, CA). Protein was detected by western blotting using the following primary antibodies:
T-cadherin (R&D Systems), adiponectin (Abcam), and β-Actin (Cell Signaling).
Statistical analysis − Data are presented as mean ± SEM. Analyses were performed using GraphPad Prism software. For LDPI analysis, a two-way repeated measured analysis of variance was performed with Bonferroni post-hoc tests. When directly comparing three or more groups, a one-or two-way analysis of variance was performed with post-hoc Student's t tests. A p value of less than 0.05 was considered statistically significant.
RESULTS
T-cadherin and adiponectin are colocalized in skeletal muscle tissue − It has been previously reported that T-cadherin is important for binding and localizing adiponectin to tumor vasculature (31) and cardiac tissue (47) . To examine this activity in skeletal muscle, immunofluorescence analysis of murine
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gastrocnemius muscle was performed. Localization of adiponectin and T-cadherin at the membranes of myocytes ( Figure 1A ) as well as capillaries ( Figure 1B ) was readily apparent in wild-type mice. Adiponectin and T-cadherin also co-localize on the luminal surface of the larger, muscular blood vessels ( Figure 1C ). Strikingly, adiponectin was not detected in the muscle of either adiponectin-deficient (APN-KO) mice or Tcadherin-deficient (Tcad-KO) mice, suggesting that T-cadherin is required for its localization to these structures. Also of note, T-cadherin expression in muscle was markedly reduced in samples isolated from APN-KO mice. In contrast to these observations with the Tcad-KO mice, deficiency of AdipoR1 or AdipoR2 had little or no effect on the localization of adiponectin to muscle tissue. Likewise, AdipoR1-or AdipoR2-deficiency had no apparent effect on T-cadherin expression.
T-cadherin localizes adiponectin to skeletal muscle tissue − Western blot analysis of gastrocnemius muscle was performed to quantify levels of adiponectin and T-cadherin in the different experimental strains of mice (Figures 2A-C). As expected, adiponectin was not detected in the muscle lysates of APN-KO mice. Similar to the immunohistochemical analysis, adiponectin protein was also not detected in muscle lysates from Tcad-KO mice (Figures 2A,B) . Similarly, tissue levels of T-cadherin were reduced in APN-KO mice (Figures 2A,C) , suggestive of a feedback regulatory loop between adiponectin and Tcadherin. Muscle T-cadherin is detected as a double band representing the mature and propeptide forms of the protein (22) . Adiponectindeficiency led to reduction in the expression of both forms, with nearly complete disappearance of the higher molecular weight, pro-peptide containing isoform (Figure 2A ). Similar levels of T-cadherin mRNA expression in gastrocnemius muscle isolated from wild type and APN-KO mice were observed ( Figure 2D ), indicating that the regulation of T-cadherin is post-transcriptional.
Consistent with a decrease in tissuelocalized adiponectin, mice deficient in T-cadherin have elevated levels of circulating, unbound serum adiponectin ( Figure 2E ). By western blot analysis, it appears that the high molecular weight (HMW) isoform of adiponectin is selectively elevated in the serum of Tcad-KO mice ( Figure 2F ). This observation supports the notion that T-cadherin preferentially binds the HMW isoform (21) . As expected, serum adiponectin protein was not detected by ELISA or western blot in adiponectindeficient mice. Despite markedly elevated adiponectin levels in the serum of the Tcad-KO mice, adipose tissue levels of adiponectin transcript and protein are unaffected by T-cadherin deficiency ( Figures  2G-I) . Furthermore, adiponectin mRNA expression in muscle was negligible compared with that of adipose tissue and did not differ between groups. Also of note, the distribution of adiponectin isoforms in adipose tissue is not different between wild type and Tcad-KO mice ( Figure 2J ). Taken together, these data suggest that T-cadherin is critical for tissue localization of adiponectin, and that the elevated circulating adiponectin found in the Tcad-KO mouse results from its liberation from tissue rather than an increase in its synthesis.
T-cadherin is required for limb revascularization − Due to the dependence of adiponectin tissue localization on T-cadherin expression and the dependence of T-cadherin expression on adiponectin levels, further studies were performed to determine the functional significance of the protein-protein interaction in a model of peripheral artery disease (45) . Wild-type, APN-KO, and Tcad-KO mice underwent analysis in a model of unilateral hind limb ischemia where a small segment of the femoral artery, nerve and vein was ligated and excised. Limb perfusion was then monitored for 28 days using LDPI. At the time of surgery (9-11 weeks old), male APN-KO and Tcad-KO mice were of similar body weight to WT mice and did not exhibit metabolic abnormalities under the conditions of our assays (Supplemental Figure 1A-C) . Impaired recovery of the laser Doppler signal was observed in both adiponectin-deficient and Tcad-KO mice relative to isogenic wild-type mice ( Figures 3A,B) . Statistically significant reductions in LDPI were observed at 7, 14, 21 and 28 day time points.
A common clinical assessment of limb function in patients with peripheral artery disease is walking distance on a treadmill (48) . Thus, to assess functional recovery from hind limb ischemia, mice were subjected to treadmill running until exhaustion at 10 days post-surgery. Whereas, no difference in running ability between strains was detected at baseline ( Figure 3C ), after chronic ischemia APN-KO and Tcad-KO mice T-Cadherin promotes revascularization displayed reduced maximum treadmill running distance compared to wild-type mice ( Figure 3D ). Wild type mice equally utilized both limbs for running, while APN-KO and Tcad-KO mice favored their non-ischemic limb (Supplemental Figure 2) . Collectively, these data show that the decreases in reperfusion, as assessed by LDPI, in APN-KO and Tcad-KO mice correspond to functional limitations in limb performance. These data also show that APN-KO mice and Tcad-KO mice display similar phenotypes with regard to their revascularization response to chronic ischemia.
T-cadherin is essential for adiponectinmediated revascularization − We have previously reported that elevating levels of serum adiponectin by adenoviral overexpression rescues the impaired blood flow recovery of adiponectin-deficient mice in the hind limb ischemia model (8) . Thus, to determine causality for a functional interaction between T-cadherin and adiponectin, an in vivo rescue experiment was performed via the expression of exogenous adiponectin. As detailed in Figure 2E , Tcad-KO mice have higher levels of serum adiponectin than wild-type mice at baseline. As high baseline levels of adiponectin would confound an adiponectin rescue experiment in the Tcad-KO mice, a strain that was deficient in both T-cadherin and adiponectin (TA-dKO) was prepared for this purpose. Thus, the rescue of adiponectin-null mice can be directly compared in APN-KO and TA-dKO mice. As described previously (47), TA-dKO mice are viable and breed with normal Mendelian frequency.
Adiponectin was administered to APN-KO and TA-dKO mice using hydrodynamic delivery of a plasmid vector that expresses murine adiponectin (pLEV113-mADIPO-hFc). In this procedure, the plasmid is rapidly delivered in a 0.9% saline solution via tail vein injection. This results in the efficient transduction of hepatocytes that express the protein of interest (46) . One week after hydrodynamic injection, mice were subjected to hind limb ischemia surgery. At the time of surgery, blood was collected by tail vein to determine the concentration of serum adiponectin. Adiponectin levels were undetectable in control plasmid-injected APN-KO and TA-dKO mice ( Table 1 ). The impaired revascularization response observed in TA-dKO mice injected with control plasmid was not different from that of APN-KO or Tcad-KO mice injected with control plasmid. Deficiency of both adiponectin and T-cadherin did not exacerbate the impairment in revascularization beyond that of the single KO mice. APN-KO mice injected with adiponectin plasmid reached physiological levels of adiponectin one week after treatment ( Table 1) . As anticipated, replenishment of adiponectin improved blood flow recovery in adiponectin-deficient mice (Figures 4A,C) . However, adiponectin delivery did not improve blood flow recovery in TA-dKO mice ( Figures  4B,C) . These data suggest that expression of Tcadherin is required for the revascularization actions of adiponectin in the hind limb ischemia model.
T-cadherin is required for adiponectininduced migration and proliferation of endothelial cells -Revascularization as a result of chronic ischemia is largely due to an adaptive angiogenesis and/or arteriogenesis response involving endothelial cell migration and proliferation (49) . Thus, cell culture experiments were initiated to further delineate the functional relationship between T-cadherin and adiponectin. It has been previously reported that adiponectin promotes endothelial cell migration and proliferation in vitro (9, 50, 51) . The dependence of adiponectin's in vitro angiogenic activities on Tcadherin expression in endothelial cells was evaluated. Using low passage HUVECs, Tcadherin mRNA and protein expression were reduced by siRNA directed against this transcript but not by control siRNA ( Figure 5A ). The expression of other reported adiponectin binding proteins, AdipoR1 and AdipoR2, was not altered by knockdown of T-cadherin. In a scratch-induced migration assay, knockdown of T-cadherin had little or no effect on HUVEC migratory activity. The addition of recombinant adiponectin promoted migration in cells transfected with control siRNA but not in those that received T-cadherin-targeting siRNA ( Figure 5B ). In an assay of HUVEC proliferation, knockdown of T-cadherin had a small effect on BrdU incorporation into DNA. Notably, adiponectin-induced proliferation was not observed in HUVECs deficient in T-cadherin ( Figure 5C ). These data show that expression of Tcadherin is required for the ability of adiponectin to promote endothelial cell migration and proliferation in vitro.
One mechanism for the revascularization actions of T-cadherin presented here may be its ability to bind and localize adiponectin to the vascular endothelium. To determine whether a direct interaction occurs between T-cadherin and adiponectin, a co-immunoprecipitation experiment was performed. After overnight serum starvation, HUVECs were cultured in the presence or absence of HMW recombinant adiponectin (rAPN). After a brief crosslinking, cell lysates were incubated with an antibody targeting adiponectin. Protein complexes were isolated and visualized by western blotting ( Figure 5D ). An adiponectin-T-cadherin co-immunoprecipitation complex was observed in HUVECs treated with HMW adiponectin, suggesting a direct protein interaction. Thus, adiponectin binds T-cadherin on endothelial cells, corroborating previous reports that T-cadherin directly binds HMW adiponectin in co-transfected human embryonic kidney 293 cells (21) and C2C12 murine myotubes (47) .
Although AdipoR1 and AdipoR2 are not essential for localization of adiponectin to skeletal muscle ( Figures 1A, 2A) , we assessed any functional importance for these receptors in the pro-angiogenic action of adiponectin in vitro. Similar to previous experiments with T-cadherin siRNA knockdown, HUVECs were treated with siRNA targeting AdipoR1 or AdipoR2. Expression was reduced by >88% compared to control siRNA-treated cells. Surprisingly, deficiency of either AdipoR1 or AdipoR2 prevented the migratory ( Figure 5E ) and proliferative actions of adiponectin ( Figure 5F ). Additional studies should be completed to determine if AdipoR1 or AdipoR2 are functionally significant for the revascularization actions of adiponectin in vivo.
DISCUSSION
Adiponectin is almost exclusively produced by adipose tissue and it acts on cardiovascular tissues in a paracrine manner. While it is widely recognized that adiponectin has vascular-protective and pro-angiogenic actions (9-12), the membrane proteins that mediate these actions are unknown. Here, we assessed the functional interaction between adiponectin and Tcadherin, a GPI-anchored membrane protein, using both in vitro and in vivo assays. Our findings show that T-cadherin is required for localization of adiponectin to skeletal muscle, and that Tcad-KO mice are phenotypically similar to APN-KO mice in that both strains display impaired blood flow recovery compared with wild-type mice in a model of hind limb revascularization. The impaired revascularization phenotype could be rescued by the administration of adiponectin in APN-KO mice but not in mice that were lacking T-cadherin. These studies confirm the critical role of T-cadherin in ischemia-induced revascularization, and are the first to demonstrate that T-cadherin functions are essential in mediating the pro-angiogenic activity of adiponectin.
We report that adiponectin is present on the cell surfaces of the vascular endothelium and myocytes in gastrocnemius muscle tissue of wildtype mice. Adiponectin localization is not detected in the muscle of Tcad-KO mice. Based upon these data, it is reasonable to hypothesize that Tcadherin facilitates the ability of adiponectin to promote vascular function through its localization of this adipokine to target tissues. Consistent with these observations, it has also been reported that T-cadherin is important for the localization of adiponectin to tumor vasculature (31) and the heart (47). Adiponectin is abundantly present in the serum of wild-type mice, but its levels in serum are elevated ~4-fold in mice that lack Tcadherin. Since the expression of adiponectin protein and transcript by adipose tissue is not influenced by a deficiency in T-cadherin, it would appear that approximately 75% of the organism's total adiponectin is bound to tissue via a Tcadherin-dependent mechanism. In contrast to Tcadherin, the localization of adiponectin to skeletal muscle tissue was not dependent on expression of either AdipoR1 or AdipoR2. Thus, while AdipoR1 may have important metabolic effects in skeletal muscle (16, 19, 20) , it appears that T-cadherin is primarily responsible for binding and localizing adiponectin to that tissue. Furthermore, based upon these data, the presence of AdipoR1 and AdipoR2 is not sufficient to enable a revascularization response to the administration of adiponectin. However, since only single knockout mouse models were examined in this study, we cannot exclude an effect of simultaneous AdipoR1-and AdipoR2-deficiency on adiponectin localization.
Further evidence of a functional Tcadherin-adiponectin interaction comes from the
T-Cadherin promotes revascularization
observation that T-cadherin protein expression in skeletal muscle is markedly repressed in APN-KO mice. In contrast, T-cadherin mRNA expression is not altered in APN-KO mice compared with wild type, indicating that this regulation is posttranscriptional. Denzel et al. also observed the coordinate regulation of adiponectin and Tcadherin expression in heart (47) . Similarly, a correlation between adiponectin and T-cadherin expression was described in a model of liver fibrosis where elevated serum adiponectin was associated with elevated hepatic expression of Tcadherin (52) . Thus it is tempting to speculate that adiponectin signals through T-cadherin to support T-cadherin's expression via a positive feedback loop mechanism. Accordingly, altered expression of T-cadherin under physiological or pathological conditions could then lead to changes in the amounts of circulating and tissue-localized adiponectin.
Adiponectin is an unusual receptor ligand because it circulates at very high levels and has a complex structure. In humans, adiponectin levels in serum range from 3 to 30 μg/ml, and it represents approximately 0.01% of the total serum protein (53) . In contrast, growth factors and cytokines that interact with conventional cell surface receptors are present in the circulation at levels that are three orders of magnitude lower. Adiponectin is comprised of a globular head and a collagenous tail that allow the protein to form stable trimers, hexamers, and higher order oligomers (360-540kDa). These properties suggest that adiponectin is structurally and functionally similar to collectin proteins that interact with a variety of macromolecules at relatively low affinities. Collectin proteins, such as C1q and lung surfactant proteins, either circulate at high levels or are localized to mucosal surfaces in the lung and gastrointestinal tract where they function to protect tissues from environmental stress (54) . Accordingly, collectin-like properties have been attributed to adiponectin, including an ability to opsonize apoptotic cells and bind bacterial lipopolysaccharides (55, 56) . On the other hand, it is also clear that adiponectin can activate intracellular signaling cascades that control cellular phenotype (e.g. (9,12) ), suggesting that these effects are mediated by specific receptors on the cell surface. However, given its structure and abundance, it is likely that adiponectin's receptor interactions will be atypical. In particular, it is difficult to imagine a classical, high affinity ligand-receptor interaction for adiponectin because the receptor would be in a constant state of saturation at physiological levels of this adipokine. In view of these considerations, T-cadherin may serve as a membrane-associated signal transducer for adiponectin. Like adiponectin, T-cadherin is abundantly present on the surface of some cell types, and it may serve as a low-affinity receptor for adiponectin. Alternatively, T-cadherin may have a co-receptor function and be required for the proper presentation of adiponectin to a classical high-affinity receptor, such as AdipoR1 or AdipoR2. Recently, Denzel et al. identified Tcadherin as critical for the cardiac-protective effects of adiponectin in models of cardiac hypertrophy and ischemia-reperfusion (47) . Taken together with the current study, this work highlights the critical role for T-cadherin in mediating the protective effects of adiponectin in the cardiovascular system. While it's clear that T-cadherin localizes adiponectin to various tissues, it's not well understood how T-cadherin initiates intracellular signaling since it lacks a transmembrane and intracellular domain. However, it has been reported that T-cadherin can function independently of adiponectin by promoting LDLinduced intracellular calcium release (57), facilitating release of insulin from pancreatic β-cells (58) , and inhibiting insulin signaling in endothelial cells via PI3K/Akt/mTOR axis (33). Since T-cadherin is found to co-localize with caveolin, it's possible that interactions between Tcadherin and other proteins in caveolae or lipid rafts may result in intracellular signaling (59) . This concept of receptor internalization is consistent with a report of T-cadherin nuclear localization (60) . T-cadherin has also been shown to promote endothelial survival via binding interactions with integrin-linked kinase (61) and Grp78 (62) . However, these studies did not evaluate Tcadherin signaling downstream of adiponectin, nor a functional relationship between T-cadherin and AdipoR1 and/or AdipoR2.
Peripheral artery disease is a serious condition of reduced lower limb perfusion that is estimated to affect 15-20% of the elderly population (63). The development of peripheral artery disease is associated with smoking,
advanced age and metabolic syndrome, and it represents a major unmet clinical need (64) . Our results suggest that adiponectin has therapeutic benefit for ischemic limb disease and that this effect occurs via an interaction with T-cadherin. Consistent with this hypothesis, it is reported that circulating levels of HMW adiponectin are inversely associated with development of peripheral artery disease (65) . Moreover, genome wide association studies have linked T-cadherin with peripheral artery disease risk factors and comorbidities (37, 44, 66) . Interestingly, polymorphisms in the T-cadherin gene are also associated with circulating levels of adiponectin in human subjects (34) (35) (36) (37) (38) (39) , and these reports are reminiscent of observations made here of elevated serum adiponectin levels in Tcad-KO mice. Collectively, these findings highlight the importance of the T-cadherin-adiponectin interaction in vascular homeostasis and suggest that further studies on this system could lead to a better understanding of ischemic diseases. Figure 1 . T-cadherin and adiponectin are co-localized in skeletal muscle tissue. A) Representative confocal images of adiponectin and T-cadherin immunofluorescence in gastrocnemius muscle isolated from wild-type, APN-KO, Tcad-KO, AdipoR1-KO and AdipoR2-KO mice. DAPI was used as a nuclear stain. B) Skeletal muscle isolated from wild-type mice was stained with antibodies targeting adiponectin, T-cadherin and an endothelial cell marker (CD31). Hoechst was used as a nuclear stain and white arrows indicate co-localization in confocal images. C) Major vessels in skeletal muscle were observed for both adiponectin and T-cadherin expression. Co-localization was observed on the luminal surface of vessels.
FIGURE LEGENDS

Figure 2. T-cadherin localizes adiponectin to skeletal muscle tissue.
A) Adiponectin and T-cadherin antibodies were used to probe a western blot of skeletal muscle isolated from wild-type, APN-KO, Tcad-KO, AdipoR1-KO and AdipoR2-KO mice. Tubulin was used to control for equal protein loading. ImageJ was used to quantify B) adiponectin and C) T-cadherin protein expression. Mean ± SEM, n = 3, *p < 0.05. D) T-cadherin mRNA expression assessed in gastrocnemius muscle isolated from wild-type and APN-KO mice. Mean ± SEM, n = 3, p > 0.05. E) Serum was harvested from wild-type, APN-KO and Tcad-KO mice and adiponectin concentration was measured by ELISA (B-Bridge). Mean ± SEM, n = 8, *p < 0.05. F) Representative native western blot of mouse serum using anti-adiponectin primary antibody (R&D Systems). G) Adipose tissue and gastrocnemius muscle isolated from wild-type, APN-KO and Tcad-KO mice were used to quantify adiponectin mRNA expression by Real-Time PCR. Mean ± SEM, n = 3, p > 0.05. H) Adiponectin protein expression was measured in adipose tissue by western blot (reduced and denatured) and I) quantified using ImageJ. J) Using native protein samples, the relative distribution of adiponectin isoforms was assessed in adipose tissue by western blot. 
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